Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Task Force Mammography Guidelines Present Challenges And Opportunities

This article was originally published in The Gray Sheet

Executive Summary

Mammography coverage policies among public and private payers are not likely to be restricted, at least in the near term, by the U.S. Preventive Services Task Force's new breast cancer screening guidelines, but prospects for longer-term adjustments remain

You may also be interested in...

Device Center Secures $3 Million More In Budget Agreement; Boosts For NIH, Cybersecurity

FDA’s Center for Devices and Radiological Health will gain $3 million more in funding compared to 2015, NIH will get a $2 billion boost, and Precision Medicine and BRAIN initiatives will be well-funded under a budget agreement reached by Congress Dec. 15, slated for Congress’ approval in the next several days.

Breast Cancer Screening Advice Confusing Following Cancer Society Update, Industry Says

The American Cancer Society’s Oct. 20 update to breast cancer screening guidelines for mammograms starting at age 45, rather than its prior recommendation to start at age 40, for average risk women conflicts with other groups’ recommendations, is confusing and potential “risky”, say the imaging industry and some medical groups.

Evidence Lacking To Assess Added Dense-Breast, 3-D Mammo Cancer Screens, Task Force Says

In a draft recommendation, the U.S. Preventive Services Task Force says evidence is "insufficient" to assess 3D tomosynthesis for breast cancer screening, as well as for additional dense-breast screening by any modality.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts